Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy.

Link to article at PubMed

Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy.

J Thromb Haemost. 2013 May 6;

Authors: Spyropoulos A, Albaladejo P, Godier A, Greinacher A, Hron G, Levy J, Samama C, Douketis J, The Subcommittee on Predictive Variables of the Scientific Standardization Committee of the ISTH

Abstract
The periprocedural management of patients on antiplatelet (AP) therapy such as aspirin (ASA), or P2Y12 receptor antagonists (clopidogrel, ticagrelor, and prasugrel), for the primary or secondary prevention of cardiovascular disease, is an increasingly common clinical problem [1]. Approximately 10 - 15% of normal platelet function is restored for each day of interruption of AP therapy and therefore it would take 7 - 10 days for an entire platelet pool to be restored [2]. Cohort studies involving patients on combined anticoagulant and ASA therapy typically stopped ASA 7-10 days before the procedure or surgery[3-5](,) [6, 7] When resuming AP therapy, the maximum antiplatelet effect of ASA can occur within minutes, and with agents like clopidogrel, when administered with a 150-600 mg loading dose, maximum platelet inhibition can occur within 12 -15 hours after administration [8, 9]. Cohort studies involving patients on anticoagulant therapy and ASA typically resumed ASA within 24 hours for most surgical procedures [6, 7]. This article is protected by copyright. All rights reserved.

PMID: 23647986 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.